

RECEIVED
CENTRAL FAX CENTER
DEC 30 2008

TELECOPIER TRANSMISSION

TO: USPTO

FAX NO.: (571) 273-8300

FROM: James V. Costigan

CHARGE : 1360-001


(IF THERE ARE ANY PROBLEMS REGARDING THIS TRANSMISSION, PLEASE
CALL (212) 302-8989

CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY BE SUBJECT
TO THE ATTORNEY-CLIENT PRIVILEGE OR ATTORNEY WORK PRODUCT EXCLUSION.

THIS FACSIMILE IS ONLY INTENDED FOR THE DESIGNATED RECIPIENT (S). ANY RECIPIENT OTHER
THAN THE DESIGNATED RECIPIENT(S) IS HEREBY NOTIFIED THAT ANY DISCLOSURE OR USE OF THE
INFORMATION IS UNAUTHORIZED AND PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN

I hereby certify that this correspondence (Amendment 6 pages) in regard to
Serial No. 110/762,714 is being facsimiled to the United States Patent and
Trademark Office via fax number (571) 273-8300 on the date shown below.


James V. Costigan

December 30, 2008

RECEIVED
CENTRAL FAX CENTER
DEC 30 2008

Docket No.: 1360-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE-
PATENT OPERATIONS

In re Application of:

Maxwell Gordon

Group Art Unit: 1617

Serial No.: 10/762,714

Examiner: Claytor, Deirdre Renee

Filed: January 22, 2004

For: ANALGETIC DOSAGE FORMS THAT ARE RESISTANT TO
PARENTERAL AND INHALATION DOSING AND HAVE REDUCED SIDE
EFFECTS

New York, NY 10036
December 30, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

This Amendment is being filed in response to the Office
Action that was mailed September 30, 2008. Kindly amend the
above identified application as follows: